Argenx Se (ARGX) Income from Continuing Operations (2016 - 2026)
Argenx Se (ARGX) posted Income from Continuing Operations of 498000000.0 for Q1 2026, up 23.48% on a QoQ basis from 403294000.0 in Q4 2025, and up 111.59% year-over-year from 235361000.0 in Q1 2025.
Argenx Se (ARGX) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Argenx Se's Income from Continuing Operations history runs 11 years deep, the most recent figure standing at 498000000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 111.59% year-over-year to 498000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1574246000.0 (up 301.35% YoY) and the FY2025 annual result came in at 1292035000.0, up 55.1% from the prior year.
- Income from Continuing Operations was 498000000.0 for Q1 2026 at Argenx Se, up from 403294000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 498000000.0 in Q1 2026 and bottomed at 674167000.0 in Q2 2022.
- A 5-year average of 109000058.82 and a median of 83851000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 730.63% — and 2025, when it soared 2012.28%.
- Argenx Se's Income from Continuing Operations stood at 41238000.0 in 2022, then soared by 48.35% to 61178000.0 in 2023, then soared by 37.06% to 83851000.0 in 2024, then surged by 380.97% to 403294000.0 in 2025, then climbed by 23.48% to 498000000.0 in 2026.
- Business Quant data shows ARGX's Income from Continuing Operations at 498000000.0 in Q1 2026, 403294000.0 in Q4 2025, and 386053000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 205.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 498.00 Mn |
| Dec 31, 2025 | 403.29 Mn |
| Sep 30, 2025 | 386.05 Mn |
| Jun 30, 2025 | 286.90 Mn |
| Mar 31, 2025 | 235.36 Mn |
| Dec 31, 2024 | 83.85 Mn |
| Sep 30, 2024 | 88.02 Mn |
| Jun 30, 2024 | -15.00 Mn |
| Mar 31, 2024 | -74.35 Mn |
| Dec 31, 2023 | 61.18 Mn |
| Sep 30, 2023 | 83.28 Mn |
| Jun 30, 2023 | -83.86 Mn |
| Mar 31, 2023 | 76.18 Mn |
| Dec 31, 2022 | 41.24 Mn |
| Sep 30, 2022 | 241.02 Mn |
| Jun 30, 2022 | -674.17 Mn |
| Mar 31, 2022 | 216.00 Mn |
| Dec 31, 2021 | -244.88 Mn |
| Sep 30, 2021 | 230.87 Mn |
| Jun 30, 2021 | 106.90 Mn |